版本:
中国

BRIEF-Bristol-Myers announces availability of Orencia subcutaneous administration option for patients above 2 yrs of age with moderately to severely active polyarticular JIA

June 8 Bristol-myers Squibb Co

* Bristol-Myers Squibb announces availability of new Orencia (abatacept) subcutaneous administration option for patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic Arthritis (JIA) Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐